This one kind of just blows my mind, for a number of reasons. You look at what the company has in finished products and revenues steadily rising this year alone thus far BEFORE the commercial launch and all out marketing blitz by Novartis subsidiary Sandoz the revenues were already rising in 2019 40-50% year over year Q after Q.
So me being all about the money said well shit, now they are launching this new product in a market that has been in a shortage situation in 2018-2019 and back-to-school season approaches, concerns about serious food allergies are on the minds of many parents, school administrators, and teachers. Right at the end of the Q ending June 30th was the perfect time to launch Symjempi.
Q1 2019 $4,905,772 (2018 $3,179,235)
Q2 2019 $5,764,899 (2018 $3,920,566)
Q3 2019 $??.?????? Next Thursday with first Syjhemi $$
Now I am not a math wiz or anything but with revenues already jumping 40-50% year over year every quarter it seems to me that this next ER November 6th should by all signs show a 100%+ increase year over year so I figure for myself under $1.50 this is a no brainer.
Me being a put away the hype show me the numbers, more importantly show me the growing numbers and the thing, in this case the 2 things that will make those numbers grow even more rapidly. Kind of like yeah she is pretty and all, but, I have to live with this gal, can she cook and is she crazy? Tell me about the things that matter long term.
ADMP under $1.50 was already a nicely baked cake, needing nothing as it was moist and sweet. Then the icing comes along, the Zimhi in the midst of an opioid epidemic and also not only dealing with shortages as the ephedrine market was but with the increase in fentanyl use causing people to OD in record numbers an health/emergency responders finding most needing 2-3+ of the normal injectors to save them perfect timing yet again another slot filled.
A built in partner one would think in the Novartis subsidiary Sandoz winner winner chicken dinner.
People have totally had the wool pulled over their eyes here, everything going so well and they get talked into thinking the world is coming to and end and everything depends on this or that or this persons missteps or that, totally ignoring the obvious, the elephant in the room so to speak.
IMHO this stock under a $1 is a steal and with approval forget about it, how will those revenue numbers be looking? I would venture to say 6 months from now they won't be rising 100%+ year over year I won't venture to guess but will naloxone injections jumping 100% in three years with 70,000 fatal overdoses in 2018 they could be up slightly, one would think as it is and will be the only one with a double dose, no need to do as they do now hit them with average of two and many 4-5 now 1 for most 2 for some but again with fenatanyl and opioid overdoses its getting it into them in time, a double dose from the jump saves precious time.
Should happen today and has a built in partner IMO right there in Sandoz and if it doesn't big deal if the price is under $1-1.50 because the number are rising rapidly already. Watch this, if you aren't in it, watch it, if it dips as next Thursday even more proof of why this should be trading right now without Zimhi at $1.50 its all about the revenues and them rising at a steady rapid pace.
Peace out.
